Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 4Breast Neoplasms 3Stomach Neoplasms 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Advanced Breast Cancer 1

Interventions

Docetaxel 7Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Biopsy 3Vorinostat 2Trastuzumab 2Taxes 2Radiotherapy 2Polymerase Chain Reaction 2Immunohistochemistry 2Gene Expression Profiling 2Flow Cytometry 2zanidatamab 1vandetanib 1trastuzumab deruxtecan 1tipifarnib 1tanespimycin 1spartalizumab 1sargramostim 1pembrolizumab 1larotrectinib 1fluoromisonidazole 1entrectinib 1entinostat 1ceralasertib 1alectinib 1X-Ray Therapy 1Thalidomide 1Specimen Handling 1Rubidium-82 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × ceralasertib × Breast × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡